| Population 2017 |
30 million |
| |
| | | | | |
| Estimates of TB burden*, 2017 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
20 |
(12–31) |
67 |
(39–103) |
| Mortality (HIV+TB only) |
7.7 |
(3.8–13) |
26 |
(13–43) |
| Incidence (includes HIV+TB) |
107 |
(69–153) |
359 |
(232–512) |
| Incidence (HIV+TB only) |
18 |
(9–30) |
60 |
(30–101) |
| Incidence (MDR/RR-TB)** |
3.9 |
(1.6–7.2) |
13 |
(5.5–24) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2017 |
| |
0-14 years |
> 14 years |
Total |
| Females |
5.2 |
(2.1–8.2) |
35 |
(14–56) |
40 |
(19–62) |
| Males |
5.7 |
(2.4–9.1) |
61 |
(25–97) |
67 |
(31–102) |
| Total |
11 |
(6.2–16) |
96 |
(54–137) |
107 |
(69–153) |
| |
| | | | | |
| TB case notifications, 2017 |
|
| Total cases notified |
57 877 |
| Total new and relapse |
54 401 |
| - % tested with rapid diagnostics at time of diagnosis |
|
| - % with known HIV status |
59% |
| - % pulmonary |
94% |
| - % bacteriologically confirmed among pulmonary |
53% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2017 |
51% (36–79) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2017 |
0.27 (0.14–0.42) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2017 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
3 613 |
11% |
| - on antiretroviral therapy |
1 401 |
39% |
| |
| | | | | |
| Drug-resistant TB care, 2017 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
2 000
(1 200–2 900) |
| Estimated % of TB cases with MDR/RR-TB |
2.5% (1.1–4.3) |
14% (10–18) |
|
| % notified tested for rifampicin resistance |
<1% |
6% |
534 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
0 |
| Laboratory-confirmed cases |
MDR/RR-TB: 534, XDR-TB: 0 |
| Patients started on treatment **** |
MDR/RR-TB: 534, XDR-TB: 0 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New cases registered in 2016 |
27% |
53 980 |
| Previously treated cases registered in 2016 |
28% |
7 069 |
| HIV-positive TB cases registered in 2016 |
0% |
2 773 |
| MDR/RR-TB cases started on second-line treatment in 2015 |
72% |
227 |
| XDR-TB cases started on second-line treatment in 2015 |
|
0 |
| |
| | | | | |
| TB preventive treatment, 2017 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
13% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
|
| |
| | | | | |
| TB financing, 2018 |
|
| National TB budget (US$ millions) |
46 |
| Funding source: 7% domestic, 12% international, 80% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed | | |
| | | | | |